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Cervical cancer is a disease with a high social and 
psychological burden, for which screening has 
shown efficacy and cost effectiveness.1 However, 
implementation of cervical cancer screening has 
been proving difficult in several European countries 
(eg, Bulgaria and Romania), resulting in delayed 
adoption of effective treatment. After a 2010 
European Parliament resolution called for the 
enactment of cancer prevention programmes (mainly 
cervical, breast, and colon cancer), some European 
Union member states set up screening programmes, 
while others began to implement organised cervical 
cancer screening.2 Notably, organised screening 
is more effective than spontaneous screening in 
reducing cervical cancer incidence and mortality.3 
However, even in some European countries with 
organised screening, coverage is inadequate. The 
incidence of cervical cancer is higher in women 
who have not been invited to screening or have 
not accepted the invitation to be screened.4 These 
considerations suggest a close connection between 
scientific evidence (ie, incidence and mortality 
rates) and the implementation of a sound screening 
programme. 
In The Lancet Oncology, Salvatore Vaccarella and 
colleagues5 provide comprehensive information about 
cervical cancer incidence in six Baltic and central and 
eastern European countries (BCEE)—Estonia, Latvia, 
Lithuania, Belarus, Bulgaria, and Russia—as well as 
projections for cervical cancer rates for 2017–40 in 
these countries. A previous article6 reported high 
cervical cancer incidence in BCEE states, without 
estimating future projections, and had suggested that 
preventive actions should be urgently implemented. 
The latest study by Vaccarella and colleagues therefore 
completes the information about cervical cancer in 
BCEE states, and its findings are interesting for many 
reasons. The authors used population-based registry 
data and an age–period–cohort model approach 
to develop cervical cancer incidence projections in 
two scenarios: no change (ie, continued absence of 
screening; scenario A) and introduction of screening 
from 2017 onwards (scenario B). Without effective 
screening programmes, cervical cancer incidence is 
expected to continue to rise in nearly all six BCEE 
countries studied, whereas the adoption of effective 
prevention and screening would achieve a gradual 
reduction of up to 50–60% in cervical cancer by 2040.5 
In this age–period–cohort model, the period effect 
could be viewed as the result of the enactment of 
effective screening programmes that would reduce 
the cervical cancer incidence trend and the cohort 
effect as the action exerted by human papillomavirus 
(HPV) vaccination on the cohorts that would 
subsequently undergo screening. The period effect 
will also correlate with screening coverage. 
These findings portray a dismal scenario, and 
should stimulate further consideration because they 
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emphasise the need for urgent adoption of health 
policy actions and initiatives tailored to each country 
and area. Such policies should aim, on the one hand, to 
improve cervical cancer prevention and screening, and 
on the other, to manage the large number of cervical 
cancer cases that are expected in clinical practice. 
The findings of the study by Vaccarella and colleagues 
suggest  the value of studying neighbouring countries 
such as Romania, which is characterised by high 
mortality and incidence rates and low screening 
coverage.1 Additionally, all the countries reviewed 
by the authors have a high incidence of cervical 
cancer, largely opportunistic screening, low screening 
coverage, and use of the Pap smear as the primary test 
(except in the St Petersburg area of Russia, where the 
HPV test is in use). Screening in BCEE countries could 
be re-organised by replacing the Pap smear with the 
more sensitive HPV test,2 thus creating a new era for 
cervical cancer screening in these countries. A further 
strategy to enhance participation is self-sampling, 
which has shown adequate accuracy in HPV testing.7 
Indeed, according to a 2015 study,8 home mailing 
of a self-sampling kit proved effective in increasing 
screening participation, even in programmes that 
used the HPV test as the primary test. This approach 
would be especially useful for young women aged 
younger than 39 years, for whom screening is a high 
priority, but might also make testing more practical 
and acceptable to older  women (aged older than 
59 years). In addition to increasing participation 
directly, this approach might also ensure high rates of 
compliance in subsequent rounds of screening.
Although well designed, the study by Vaccarella and 
colleagues has some minor limitations, especially with 
regards to the data from Russia. These data must be 
considered with caution, both because they come 
from local registries (rather than the population-
based cancer registries used for the other countries) 
and because the International Classification Disease, 
9th revision, codes are not always accurate.6 Indeed, 
several deaths from uterine cancer are sometimes 
simply coded as tumour of the uterus, which 
provides no information about whether they were 
caused by cervical cancer or tumours of the body of 
the uterus.4 According to Mathers and colleagues,9 
the quality level of data coming from Russia is D2 
(ie, suboptimum). This low quality might result in 
skewed projections and strategies. Nonetheless, the 
projections estimated by Vaccarella and colleagues 
provide a useful scenario that could be reassessed if 
higher quality data from Russia become available. 
The continuous improvement in the quality of 
epidemiological data collection provides crucial 
support to public health decision-makers. Russia is 
actually a high-income country10 and could therefore 
potentially afford to increase health-care spending 
and improve the quality of its epidemiological data.
In conclusion, cervical cancer screening programmes 
in BCEE countries should be based on existing 
European guidelines and harness the facilities, 
personnel, and economic structures available in each 
country and area. However—and crucially—this is not 
merely a health-related issue, because prioritisation 
of cancer prevention will also go a long way towards 
reducing social inequalities in these countries.
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